Open trial of imipenem/cilastatin therapy for serious bacterial infections.

Abstract

Imipenem is a new beta-lactam antibiotic with a wide spectrum of activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The efficacy and toxicity of this drug, when administered parenterally in combination with the dehydropeptidase I inhibitor cilastatin, were studied in 41 hospitalized patients with serious infections. Clinical cure was achieved in 26 (79%) of the 33 patients who could be evaluated and microbiologic cure in 23 (85%) of the 27 patients who could be evaluated. Adverse clinical or laboratory reactions were observed in seven (17%) of the 41 patients. Thus, imipenem/cilastatin was highly effective in the treatment of a wide variety of serious bacterial infections.

• Authors: R G Brooks, R E McCabe, K L Vosti, J S Remington
• Journal: Reviews of infectious diseases (Rev Infect Dis) 1985 Jul-Aug Vol. 7 Suppl 3 Pg. S496-505 ISSN: 0162-0886 [Print] United States
• PMID: 3901213 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Cyclopropanes
• Thienamycins
• Cilastatin
• Imipenem

Topics

• Adult
• Aged
• Bacterial Infections (drug therapy)
• Cilastatin
• Clinical Trials as Topic
• Cyclopropanes (administration & dosage, adverse effects)
• Drug Resistance, Microbial
• Drug Therapy, Combination
• Female
• Humans
• Imipenem
• Male
• Middle Aged
• Thienamycins (administration & dosage, adverse effects)